W. Michael Korn, MD, CMO @carisls #ESMO20 #ovariancancer Caris Life Sciences to Present New Ovarian Cancer Research at ESMO Virtual Congress 2020

W. Michael Korn, MD, CMO @carisls #ESMO20 #ovariancancer Caris Life Sciences to Present New Ovarian Cancer Research at ESMO Virtual Congress 2020

User Photo
ESMO

2 months
37 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

W. Michael Korn, MD, CMO of Caris Life Sciences discusses their abstract - Caris Life Sciences Presented New Ovarian Cancer Research at ESMO Virtual Congress 2020


IRVING, Texas, Sept. 15, 2020 /PRNewswire/ — Caris Life Sciences ®, a leading molecular science innovator focused on achieving the promise of precision medicine, today revealed findings from a study that may shed new light on patients with KRAS-mutated epithelial ovarian carcinoma (EOC) on their care path. These results, presented at the Virtual Congress 2020 of the European Society for Medical Oncology (ESMO), illustrate an unmet need for this patient population and indicate that targeted therapies to inhibit the response of the KRAS gene may be useful in the treatment of KRAS-mutated EOC patients.

As part of the ESMO Virtual Congress 2020, the complete findings will be discussed today during a poster show session (Abstract # 844P). KRAS Mutant Epithelial Ovarian Carcinomas (EOC) Represent Distinct Genomic Genotypes is the title of the poster.

Caris will present additional evidence from research showing the crucial role of precision medicine and molecular profiling in guiding care decisions for people with colorectal cancer and gastrointestinal tumors. Additional presentations show the potential effect of precision medicine. On Thursday, September 17, both presentations will be made available online via Caris' virtual booth.

Similar levels of PLK1 expression in both groups were found in a study evaluating polo-like kinase 1 (PLK1) in KRAS-wildtype and KRAS-mutated (MT) colorectal cancer (Abstract # 473P), indicating the potential for the efficacy of PLK1 inhibitors irrespective of KRAS status. In addition, along with PLK1 expression, microsatellite instability, and tumor mutational burden, both established immunotherapy response markers, increased. Researchers, therefore, propose that a synergistic approach to raising tumor sensitivity in PLK1-over-expressing tumors could be the combination of immunotherapy with a PLK1 inhibitor. The poster is entitled PLK1 Expression and Colorectal Cancer KRAS Mutations.

A study entitled Comprehensive profiling of MDM2-amplified gastrointestinal ( GI) cancers (Abstract # 1952P), the most comprehensive profiling study to investigate MDM2-amplified GI tumors, identified distinct molecular trends of MDM2-amplified GI cancers that involve WNT pathway genes, FGF signaling upregulation, and an inverse association with tumor mutational burden and microsatellite instability.

Up Next Autoplay
>